Chiadi Ndumele, MD, breaks down the cardiovascular-kidney-metabolic syndrome (CKM) guideline's glucagon-like peptide-1 (GLP-1) and kidney-protective therapy guidance—and the pharmacist's role in coordinated care.
Chiadi Ndumele, MD, PhD, MHS
Advertisement
Chiadi Ndumele, MD, PhD, MHS, is chair of the American Heart Association (AHA)/American College of Cardiology (ACC) cardio-kidney-metabolic (CKM) syndrome guideline writing committee and the director of Obesity and Cardiometabolic Research at Johns Hopkins University.
Articles by Chiadi Ndumele, MD, PhD, MHS
Chiadi Ndumele, MD, explains why the new American Heart Association (AHA)/American College of Cardiology (ACC) guideline addresses cardiovascular-kidney-metabolic (CKM) disease as one interconnected syndrome.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves First-in-Class Centanafadine for ADHD in Adults and Pediatric Patients
2
Pharmacists Are Critical to SGLT2, GLP-1 Use in CKD
3
FDA Expands Lutetium Lu 177 Vipivotide Tetraxetan to mHSPC, Nearly Doubling Eligible Population
4
Inside Phoebe Putney’s Medication Management Clinic: How One Rural Health System Saved $1 Million and Cut Readmissions
5